Free Trial
NASDAQ:DTIL

Precision BioSciences Q2 2026 Earnings Results & Report

Precision BioSciences logo
$7.57 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$7.58 +0.00 (+0.07%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Precision BioSciences missed analyst earnings expectations in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$1.26 versus the -$0.8040 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
9:30 AM ET

Precision BioSciences EPS Results

Actual EPS
-$1.26
Consensus EPS
-$0.8040
Beat/Miss
Missed by -$0.4560
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Precision BioSciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$740 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

Precision BioSciences Q2 2026 Earnings FAQ

Precision BioSciences (NASDAQ:DTIL) reported earnings of -$1.26 per share for Q2 2026, missing the consensus estimate of -$0.8040. The report was announced on Thursday, August 6, 2026.

Precision BioSciences Earnings Headlines

HC Wainwright Has Bullish Estimate for DTIL FY2026 Earnings
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Precision BioSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Precision BioSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precision BioSciences and other key companies, straight to your email.

About Precision BioSciences

Precision BioSciences (NASDAQ:DTIL) is a biotechnology company developing gene-editing therapies using its proprietary ARCUS platform. The platform is designed to make targeted changes to DNA and is being applied to investigational treatments for genetic and infectious diseases.

The company’s programs include PBGENE-HBV, an investigational therapy designed to target hepatitis B virus DNA, and PBGENE-DMD, a gene-editing program for Duchenne muscular dystrophy. These candidates remain in development and are not approved treatments.

Founded in 2006 and headquartered in Durham, North Carolina, Precision BioSciences has also pursued applications of its gene-editing technology through collaborations and licensing arrangements.

View Precision BioSciences Profile